Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

@article{Kralovics2006AcquisitionOT,
  title={Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.},
  author={Robert Kralovics and S Teo and Sai Li and Alexandre P A Theocharides and Andreas S Buser and Andr{\'e} Tichelli and Radek C. Skoda},
  journal={Blood},
  year={2006},
  volume={108 4},
  pages={1377-80}
}
An acquired gain-of-function mutation in the Janus kinase 2 (JAK2-V617F) is frequently found in patients with myeloproliferative disorders (MPDs). To test the hypothesis that JAK2-V617F is the disease-initiating mutation, we examined whether all cells of clonal origin carry the JAK2-V617F mutation. Using allele-specific polymerase chain reaction (PCR) assays for the JAK2 mutation and for the X-chromosomal clonality markers IDS and MPP1, we found that the percentage of granulocytes and platelets… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 137 extracted citations

JAK2 V617F-positive essential thrombocythemia in a patient with Klinefelter syndrome: a case report.

Cancer genetics and cytogenetics • 2010
View 5 Excerpts
Highly Influenced

Update on JAK2 Inhibitors in Myeloproliferative Neoplasm.

Therapeutic advances in hematology • 2011
View 4 Excerpts
Highly Influenced

Cytokine Signaling in Tumor Progression

Immune network • 2017
View 2 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Clinical implications of the JAK 2 V 617 F mutation in essential thrombocythemia

E Antonioli, P Guglielmelli, A Pancrazzi
Leukemia • 2005

Similar Papers

Loading similar papers…